“数”览2025年国家医保药品目录惠民生实效 群众实实在在有“医”靠

Core Insights - The National Healthcare Security Administration (NHSA) announced the 2025 version of the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List, along with the first version of the Commercial Health Insurance Innovative Drug List, effective January 1, 2024 [1] Group 1: Drug List Adjustments - A total of 114 new drugs have been added to the list, including 50 Class 1 innovative drugs, while 29 drugs that are either not clinically available or can be better replaced by other medications have been removed [3] - The total number of drugs in the directory has increased to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines, with significant improvements in coverage for key areas such as oncology, chronic diseases, mental illnesses, rare diseases, and pediatric medications [3] Group 2: Commercial Health Insurance Innovative Drug List - The first version of the Commercial Health Insurance Innovative Drug List includes 19 drugs that are highly innovative, clinically valuable, and provide significant patient benefits beyond the basic insurance coverage [5] - This list features treatments for conditions such as cancer (including CAR-T therapies), neuroblastoma, Gaucher disease, and Alzheimer's disease, which have garnered considerable social attention [5] - The new commercial drug list will be implemented nationwide on January 1, 2026 [5]